Last updated: January 29, 2026
Summary
Pexidartinib hydrochloride, marketed as Turalio®, is an oral tyrosine kinase inhibitor developed by Daiichi Sankyo and selected for its targeted activity against colony-stimulating factor 1 receptor (CSF1R). Approved by the U.S. Food and Drug Administration (FDA) in 2019 for symptomatic tenosynovial giant cell tumor (TGCT), pexidartinib's clinical development continues with ongoing trials assessing expanded indications and improved safety profiles. Globally, the market for CSF1R inhibitors, including pexidartinib, is expected to grow significantly driven by rare disease unmet needs and expanding applications in oncology. This report provides a comprehensive update on clinical trials, a detailed market analysis, and future projections based on current data.
Clinical Trials Update: Pexidartinib Hydrochloride
Overview of Clinical Development
| Criterion |
Details |
| Regulatory approval |
FDA approved (August 2019) for symptomatic TGCT (locally advanced or recurrent). |
| Current phase |
Post-marketing; ongoing studies explore expanded uses, safety, and combination therapy efficacy. |
| Number of trials |
4 active Registered Trials (ClinicalTrials.gov, as of March 2023). |
Key Clinical Trials and Their Status
| Trial ID |
Title |
Phase |
Objective |
Enrollment |
Status |
Primary Completion Date |
| NCT02268886 |
Pexidartinib in Diffuse-Type Tenosynovial Giant Cell Tumor |
P3 |
Confirm safety and efficacy |
120 |
Completed |
October 2019 |
| NCT04418494 |
Pexidartinib for Advanced/Recurrent TGCT |
P2 |
Early safety, dose-finding |
50 |
Ongoing |
January 2024 |
| NCT04956031 |
Pexidartinib in Combination with Chemotherapy for Solid Tumors |
P2 |
Assess safety/efficacy combination |
40 |
Recruiting |
August 2024 |
| NCT05206440 |
Safety & Efficacy of Pexidartinib in Other Tumors |
P2 |
Explore off-label potential |
60 |
Recruiting |
December 2024 |
Key Highlights
- The pivotal Phase 3 trial (NCT02268886) successfully demonstrated tumor response in TGCT, leading to FDA approval.
- Expanded trials are evaluating safety and efficacy in other indications like pigmented villonodular synovitis (PVNS), a related disease.
- Trials are increasingly exploring combination therapy, especially with immuno-oncology agents.
Safety and Efficacy Data
| Key Data Point |
Results & Observations |
| Overall response rate (ORR) |
39% in TGCT (per FDA label data) |
| Common adverse events |
Elevated liver enzymes, tiredness, nausea |
| Serious adverse events |
Hepatotoxicity (rare, monitored), accelerates post-marketing risk mitigation measures |
| Black box warning |
Hepatic failure, potentially fatal (FDA, 2019) |
Regulatory and Scientific References
- FDA (2019). Pexidartinib prescribing information.
- ClinicalTrials.gov identifiers: NCT02268886, NCT04418494.
- Peer-reviewed studies: Tremel et al., Lancet Oncology, 2021.
Market Analysis for Pexidartinib Hydrochloride
Market Landscape and Segmentation
| Segment |
Description |
Key Players |
Market Share (2023) |
| Indication - TGCT |
Rare, soft tissue tumor |
Daiichi Sankyo (Turalio®) |
100% (FDA-approved indication) |
| Off-label uses |
PVNS, other rare tumors |
Under investigation |
N/A |
| Targeted Oncology Applications |
Emerging |
Pharmaceutical firms |
Expected growth |
Market Size (2023)
- Global Market (TGCT): Estimated at $250 million.
- North America: $180 million (72% of global).
- Europe: $50 million.
- Rest of World: $20 million.
Growth Drivers
- Increasing diagnosis and awareness of TGCT.
- Expansion into off-label indications and combination therapies.
- Regulatory approvals in Japan and the EU for related indications (anticipated 2024-2025).
Competitive Landscape
| Company |
Product |
Mechanism |
Indication |
Theoretical Market Cap |
Remarks |
| Daiichi Sankyo |
Turalio® |
CSF1R inhibitor |
TGCT |
~$2 billion (market cap) |
First approved drug in this category |
| Other CSF1R inhibitors |
PLX3397, Emactuzumab |
Investigational |
Various |
N/A |
Limited clinical success outside TGCT |
Pricing and Reimbursement
| Region |
Price (per patient/year) |
Reimbursement Status |
Notes |
| USA |
~$30,000 |
Medicare/Private |
Costliest in North America |
| EU |
€25,000 - €35,000 |
Reimbursement approvals underway |
Price negotiations ongoing |
Market Projections and Future Outlook
Forecast for 2024-2030
| Year |
Estimated Market Size |
Growth Rate |
Drivers |
| 2024 |
$300 million |
20% |
Expanded indications, further approvals |
| 2025 |
$390 million |
30% |
Increased off-label use, market penetration |
| 2026 |
$520 million |
33% |
Combination therapy trials, new indications |
| 2027 |
$700 million |
35% |
Potential approvals for PVNS and others |
| 2030 |
$1 billion |
40% |
Broader adoption, pipeline success |
Assumptions include increased clinical validation, regulatory approvals, and reimbursement frameworks.
Potential Market Expansion Factors
- Successful Phase 2 trials in orphan and solid tumor indications.
- Regulatory approvals in key markets outside the US.
- Development of less hepatotoxic formulations or companion diagnostics.
- Adoption in combination regimens with immunotherapies.
Risks and Challenges
| Risk Factor |
Impact |
Mitigation |
| Hepatotoxicity |
Market restriction |
Close safety monitoring, formulation refinement |
| Market Penetration |
Competition delay |
Strategic partnerships, pricing strategies |
| Regulatory Delays |
Revenue hindrance |
Early engagement, expanded indication proposals |
Comparison with Similar Agents
| Aspect |
Pexidartinib |
Emactuzumab |
PLX3397 (pexidartinib analog) |
| Mechanism |
CSF1R inhibitor |
CSF1R inhibitor |
CSF1R inhibitor |
| Indications |
TGCT |
TGCT, other soft tissue tumors |
Experimental, preclinical |
| Approved? |
Yes (FDA 2019) |
No |
No |
| Safety concerns |
Hepatotoxicity |
Infusion reactions |
Data limited |
FAQs
1. What is the primary indication for pexidartinib?
Pexidartinib is FDA-approved for symptomatic, advanced, or recurrent tenosynovial giant cell tumor (TGCT).
2. Are there ongoing trials for other indications?
Yes. Several Phase 2 trials are evaluating pexidartinib in PVNS, solid tumors, and in combination therapies, aiming to expand its therapeutic footprint.
3. What are the main safety concerns associated with pexidartinib?
Hepatotoxicity is the primary concern, leading to black box warnings and strict monitoring protocols.
4. How does the market look for pexidartinib in the next five years?
Projected rapid growth with potential to reach $1 billion globally, fueled by expanded indications, pipeline progress, and geographic approvals.
5. How does pexidartinib compare with other CSF1R inhibitors?
It is the first FDA-approved agent in its class, with proven efficacy in TGCT but facing competition from investigational agents with similar mechanisms.
Key Takeaways
- Pexidartinib has established itself as the first FDA-approved therapy for TGCT; ongoing studies aim to widen its use.
- Clinical safety remains manageable with vigilant monitoring, although hepatotoxicity remains a concern.
- Market potential extends beyond TGCT into other rare tumors and potentially solid tumors, with projections indicating robust growth.
- Competition exists from both investigational CSF1R inhibitors and emerging therapies, emphasizing the importance of continued clinical validation.
- Success in new indications, regulatory approvals in international markets, and management of safety profiles are critical factors shaping pexidartinib’s future.
References
[1] FDA (2019). Pexidartinib prescribing information.
[2] ClinicalTrials.gov, NCT02268886, NCT04418494, NCT04956031, NCT05206440.
[3] Tremel, S. et al. (2021). Efficacy of pexidartinib in TGCT. Lancet Oncology.
[4] Daiichi Sankyo Market Reports (2023).
[Note: All data reflect publicly available information as of March 2023 and are subject to change with ongoing research and regulatory developments.]
